文献速递腹部介入US

消融困难评分:预测肝细胞癌经皮消融成功率的新工具提案

Ablation Difficulty Score: Proposal of a new tool to predict success rate of percutaneous ablation for hepatocarcinoma.
PubMed 文献 · Eur J Radiol · 2021-12-05

本研究基于2010至2020年前瞻性收集的585个肝细胞癌结节,分析超声引导单电极射频消融失败的相关临床与影像因素,构建消融困难评分(ADS)。总消融成功率85.5%,ADS 0、1、≥2组成功率分别为93.5%、85.8%、71.3%(p<0.001)。作者认为ADS可指导治疗决策,高危结节(ADS≥2)的RFA应谨慎评估并保留给不适合手术或肝移植的患者。

要点

  • 结节>20 mm、包膜下、血管旁、等回声及非肝硬化肝是与消融失败相关的因素。
  • ADS将风险分为低危(0分)、中危(1分)、高危(≥2分),成功率分别为93.5%、85.8%、71.3%。
  • 1年局部肿瘤进展无生存率在ADS 0、1、≥2组分别为90.2%、80.6%、72.3%(p=0.009)。

核心结论

  • 消融困难评分可作为指导肝细胞癌治疗决策的简易有用工具;高危结节(ADS≥2)的RFA应谨慎评估并保留给不适合手术或肝移植的患者。

研究设计与样本

  • 前瞻性收集2010至2020年585个经皮超声引导单电极射频消融治疗的肝细胞癌结节,采用Cox-logistic回归分析识别与消融失败相关的临床和影像因素并构建ADS。

诊断标准与关键数值

  • 消融失败相关因素包括结节大小>20 mm(p=0.002)、包膜下位置(p=0.008)、血管旁位置(p=0.024)、等回声表现(p=0.008)及非肝硬化肝(p=0.009)。ADS分组:低危0分、中危1分、高危≥2分;消融成功率分别为93.5%、85.8%、71.3%(p<0.001)。

临床应用与阅片要点

  • 作者认为ADS可作为指导肝细胞癌治疗决策的简易有用工具,高危结节(ADS≥2)的RFA应谨慎评估并保留给不适合手术或肝移植的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Identify the factors related to failure ablation after percutaneous ultrasound guided single electrode radiofrequency ablation (RFA) for hepatocarcinoma (HCC) and propose a score for improving patient selection and treatment allocation.

METHODS: From 2010 to 2020 585 HCC nodules treated with RFA were prospectively collected. Ablation Difficulty Score (ADS) was built-up according to clinical and radiological factors related to failure ablation identified by Cox-logistic regression analysis. The study population was stratified in low risk (ADS 0), intermediate risk (ADS 1), and high risk (ADS ≥ 2) of failure ablation.

RESULTS: Overall ablation success rate was 85.5%. Morbidity and mortality rates were 3.5% and 0.0%. According to per nodule analysis the following factors resulted related to failure ablation: size > 20 mm (p = 0.002), sub-capsular location (p = 0.008), perivascular location (p = 0.024), isoechoic appearance (p = 0.008), and non-cirrhotic liver (p = 0.009). The ablation success rate was 93.5% in ADS 0, 85.8% in ADS 1 and 71.3% in ADS ≥ 2 (p < 0.001). The 1-year local tumor progression (LTP) free survival was 90.2% in ADS 0, 80.6% in ADS 1, and 72.3% in ADS ≥ 2 (p = 0.009). Nodule's size > 20 mm (p = 0.014), isoechoic appearance (p = 0.012), perivascular location (p = 0.012) resulted related to lower LTP free survival.

CONCLUSION: Ablation Difficulty Score could be a simple and useful tool for guiding the treatment decision making of HCC. RFA in high risk nodules (ADS ≥ 2) should be carefully evaluated and reserved for patients not suitable for surgery or liver transplantation.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Conci, D'Onofrio, Bianco, et al. Ablation Difficulty Score: Proposal of a new tool to predict success rate of percutaneous ablation for hepatocarcinoma. Eur J Radiol. 2021. PMID: 34896959. doi:10.1016/j.ejrad.2021.110097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。